BCRX
Price
$10.07
Change
-$0.26 (-2.52%)
Updated
May 21 closing price
Capitalization
2.16B
70 days until earnings call
SGMO
Price
$0.50
Change
-$0.00 (-0.00%)
Updated
May 21 closing price
Capitalization
122.7M
82 days until earnings call
Interact to see
Advertisement

BCRX vs SGMO

Header iconBCRX vs SGMO Comparison
Open Charts BCRX vs SGMOBanner chart's image
BioCryst Pharmaceuticals
Price$10.07
Change-$0.26 (-2.52%)
Volume$4.29M
Capitalization2.16B
Sangamo Therapeutics
Price$0.50
Change-$0.00 (-0.00%)
Volume$4.25M
Capitalization122.7M
BCRX vs SGMO Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. SGMO commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and SGMO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (BCRX: $10.07 vs. SGMO: $0.50)
Brand notoriety: BCRX: Notable vs. SGMO: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 90% vs. SGMO: 52%
Market capitalization -- BCRX: $2.16B vs. SGMO: $122.7M
BCRX [@Biotechnology] is valued at $2.16B. SGMO’s [@Biotechnology] market capitalization is $122.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than SGMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while SGMO’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 6 bearish.
  • SGMO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SGMO is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а +2.23% price change this week, while SGMO (@Biotechnology) price change was +14.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.07%. For the same industry, the average monthly price growth was +10.40%, and the average quarterly price growth was -0.77%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

SGMO is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($2.16B) has a higher market cap than SGMO($123M). BCRX YTD gains are higher at: 33.910 vs. SGMO (-50.980). BCRX has higher annual earnings (EBITDA): 47.6M vs. SGMO (-123.99M). BCRX has more cash in the bank: 295M vs. SGMO (39.2M). SGMO has less debt than BCRX: SGMO (27.7M) vs BCRX (795M). BCRX has higher revenues than SGMO: BCRX (503M) vs SGMO (52.3M).
BCRXSGMOBCRX / SGMO
Capitalization2.16B123M1,758%
EBITDA47.6M-123.99M-38%
Gain YTD33.910-50.980-67%
P/E RatioN/AN/A-
Revenue503M52.3M962%
Total Cash295M39.2M753%
Total Debt795M27.7M2,870%
FUNDAMENTALS RATINGS
BCRX vs SGMO: Fundamental Ratings
BCRX
SGMO
OUTLOOK RATING
1..100
669
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3795
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for SGMO (80). This means that BCRX’s stock grew somewhat faster than SGMO’s over the last 12 months.

BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for SGMO (100). This means that BCRX’s stock grew somewhat faster than SGMO’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

BCRX's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for SGMO (95). This means that BCRX’s stock grew somewhat faster than SGMO’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SGMO (100). This means that BCRX’s stock grew similarly to SGMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXSGMO
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFSPX696.43N/A
N/A
iShares S&P 500 Index K
BISAX22.90N/A
N/A
Brandes International Small Cap Equity A
MISGX12.33N/A
N/A
Meridian Small Cap Growth Investor
RTSGX6.01N/A
N/A
Transamerica Small Cap Growth R6
OWACX25.38N/A
N/A
Old Westbury All Cap Core

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-2.52%
VCYT - BCRX
46%
Loosely correlated
-4.17%
CRNX - BCRX
40%
Loosely correlated
-4.53%
ABEO - BCRX
39%
Loosely correlated
+0.47%
BEAM - BCRX
38%
Loosely correlated
-2.99%
DNLI - BCRX
37%
Loosely correlated
-4.20%
More

SGMO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with AXON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGMO
1D Price
Change %
SGMO100%
+0.18%
AXON - SGMO
51%
Loosely correlated
-0.99%
ARRY - SGMO
48%
Loosely correlated
-7.30%
BCRX - SGMO
46%
Loosely correlated
-2.52%
RPRX - SGMO
45%
Loosely correlated
-0.79%
AGEN - SGMO
43%
Loosely correlated
-4.69%
More